188 related articles for article (PubMed ID: 30361829)
21. Comment on "MEK inhibition with trametinib and tyrosine kinase inhibition with imatinib in multifocal histiocytic sarcoma".
Voruz S; Martins F; Cairoli A; Naveiras O; Homicsko K; Missiaglia E; de Leval L; Bisig B; Michielin O; Blum S
Haematologica; 2018 Mar; 103(3):e130. PubMed ID: 29491129
[No Abstract] [Full Text] [Related]
22. The role of MEK inhibitors in the treatment of metastatic melanoma.
Grimaldi AM; Simeone E; Ascierto PA
Curr Opin Oncol; 2014 Mar; 26(2):196-203. PubMed ID: 24419498
[TBL] [Abstract][Full Text] [Related]
23. EGFR and HER2 signals play a salvage role in MEK1-mutated gastric cancer after MEK inhibition.
Mizukami T; Togashi Y; Sogabe S; Banno E; Terashima M; De Velasco MA; Sakai K; Fujita Y; Tomida S; Nakajima TE; Boku N; Nishio K
Int J Oncol; 2015 Aug; 47(2):499-505. PubMed ID: 26081723
[TBL] [Abstract][Full Text] [Related]
24. Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma.
Tolcher AW; Patnaik A; Papadopoulos KP; Rasco DW; Becerra CR; Allred AJ; Orford K; Aktan G; Ferron-Brady G; Ibrahim N; Gauvin J; Motwani M; Cornfeld M
Cancer Chemother Pharmacol; 2015 Jan; 75(1):183-9. PubMed ID: 25417902
[TBL] [Abstract][Full Text] [Related]
25. Identification of diverse activating mutations of the RAS-MAPK pathway in histiocytic sarcoma.
Shanmugam V; Griffin GK; Jacobsen ED; Fletcher CDM; Sholl LM; Hornick JL
Mod Pathol; 2019 Jun; 32(6):830-843. PubMed ID: 30626916
[TBL] [Abstract][Full Text] [Related]
26. Inhibiting MEK in MAPK pathway-activated myeloma.
Heuck CJ; Jethava Y; Khan R; van Rhee F; Zangari M; Chavan S; Robbins K; Miller SE; Matin A; Mohan M; Ali SM; Stephens PJ; Ross JS; Miller VA; Davies F; Barlogie B; Morgan G
Leukemia; 2016 Apr; 30(4):976-80. PubMed ID: 26228812
[No Abstract] [Full Text] [Related]
27. MAP2K1 and MAP3K1 mutations in Langerhans cell histiocytosis.
Nelson DS; van Halteren A; Quispel WT; van den Bos C; Bovée JV; Patel B; Badalian-Very G; van Hummelen P; Ducar M; Lin L; MacConaill LE; Egeler RM; Rollins BJ
Genes Chromosomes Cancer; 2015 Jun; 54(6):361-8. PubMed ID: 25899310
[TBL] [Abstract][Full Text] [Related]
28. Response to Trametinib of a Pulmonary Langerhans Cell Histiocytosis Harboring a MAP2K1 Deletion.
Lorillon G; Jouenne F; Baroudjian B; de Margerie-Mellon C; Vercellino L; Meignin V; Lebbe C; Vassallo R; Mourah S; Tazi A
Am J Respir Crit Care Med; 2018 Sep; 198(5):675-678. PubMed ID: 29694792
[No Abstract] [Full Text] [Related]
29. Trametinib: a novel signal transduction inhibitor for the treatment of metastatic cutaneous melanoma.
Chung C; Reilly S
Am J Health Syst Pharm; 2015 Jan; 72(2):101-10. PubMed ID: 25550132
[TBL] [Abstract][Full Text] [Related]
30. Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms.
Diamond EL; Durham BH; Haroche J; Yao Z; Ma J; Parikh SA; Wang Z; Choi J; Kim E; Cohen-Aubart F; Lee SC; Gao Y; Micol JB; Campbell P; Walsh MP; Sylvester B; Dolgalev I; Aminova O; Heguy A; Zappile P; Nakitandwe J; Ganzel C; Dalton JD; Ellison DW; Estrada-Veras J; Lacouture M; Gahl WA; Stephens PJ; Miller VA; Ross JS; Ali SM; Briggs SR; Fasan O; Block J; Héritier S; Donadieu J; Solit DB; Hyman DM; Baselga J; Janku F; Taylor BS; Park CY; Amoura Z; Dogan A; Emile JF; Rosen N; Gruber TA; Abdel-Wahab O
Cancer Discov; 2016 Feb; 6(2):154-65. PubMed ID: 26566875
[TBL] [Abstract][Full Text] [Related]
31. Improvement of hereditary palmoplantar keratoderma with oral trametinib.
Song H; Dzuali F; Chi SN; Treat JR; Huang JT
Pediatr Dermatol; 2019 Jan; 36(1):e48-e49. PubMed ID: 30548577
[TBL] [Abstract][Full Text] [Related]
32. MEK Inhibitors in the Treatment of Metastatic Melanoma and Solid Tumors.
Grimaldi AM; Simeone E; Festino L; Vanella V; Strudel M; Ascierto PA
Am J Clin Dermatol; 2017 Dec; 18(6):745-754. PubMed ID: 28537004
[TBL] [Abstract][Full Text] [Related]
33. Mutually exclusive recurrent KRAS and MAP2K1 mutations in Rosai-Dorfman disease.
Garces S; Medeiros LJ; Patel KP; Li S; Pina-Oviedo S; Li J; Garces JC; Khoury JD; Yin CC
Mod Pathol; 2017 Oct; 30(10):1367-1377. PubMed ID: 28664935
[TBL] [Abstract][Full Text] [Related]
34. Identification of an "Exceptional Responder" Cell Line to MEK1 Inhibition: Clinical Implications for MEK-Targeted Therapy.
Gannon HS; Kaplan N; Tsherniak A; Vazquez F; Weir BA; Hahn WC; Meyerson M
Mol Cancer Res; 2016 Feb; 14(2):207-15. PubMed ID: 26582713
[TBL] [Abstract][Full Text] [Related]
35. Prospects for MEK inhibitors for treating cancer.
Martin-Liberal J; Lagares-Tena L; Larkin J
Expert Opin Drug Saf; 2014 Apr; 13(4):483-95. PubMed ID: 24597490
[TBL] [Abstract][Full Text] [Related]
36. Trametinib for progressive pediatric low-grade gliomas.
Kondyli M; Larouche V; Saint-Martin C; Ellezam B; Pouliot L; Sinnett D; Legault G; Crevier L; Weil A; Farmer JP; Jabado N; Perreault S
J Neurooncol; 2018 Nov; 140(2):435-444. PubMed ID: 30097824
[TBL] [Abstract][Full Text] [Related]
37. Comment on: Langerhans cell histiocytosis with BRAF p.N486_P490del or MAP2K1 p.K57_G61del treated by the MEK inhibitor trametinib.
Vicenzi P; Ray A
Pediatr Blood Cancer; 2021 Apr; 68(4):e28776. PubMed ID: 33089615
[No Abstract] [Full Text] [Related]
38. Promises from trametinib in RAF active tumors.
Sausville EA
N Engl J Med; 2012 Jul; 367(2):171-2. PubMed ID: 22663012
[No Abstract] [Full Text] [Related]
39. MEK inhibition in BRAF-mutated melanoma.
MacKenzie A; Boycott K
N Engl J Med; 2012 Oct; 367(14):1364-5. PubMed ID: 23034029
[No Abstract] [Full Text] [Related]
40. MEK inhibition in BRAF-mutated melanoma.
Ascierto PA
N Engl J Med; 2012 Oct; 367(14):1364; author reply 1365. PubMed ID: 23034028
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]